Biofrontera Inc. Form 8-K Summary
Business Context and Reporting Period
Biofrontera Inc., a Delaware corporation listed on Nasdaq under BFRI and BFRIW, filed this Current Report on October 24, 2022, reporting events occurring on October 3 and October 24, 2022. The filing concerns the appointment and compensation arrangements of a new Chief Financial Officer. It is not a quarterly or annual financial-results filing.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash-flow, margin, debt, liquidity, or other operating-financial metrics. It does disclose compensation obligations associated with the CFO appointment, including an annual base salary of $355,000, a $25,000 signing bonus, a potential annual bonus of up to 40% of base salary, and 100,000 stock options.
Material Changes and Management Actions
- Fred Leffler was appointed Chief Financial Officer effective October 24, 2022.
- The company entered into an employment agreement with Mr. Leffler on October 3, 2022.
- Mr. Leffler previously held financial, consulting, restructuring, and operations roles at McKinsey & Company, FTI Consulting, Rockcreek, General Electric, and Sun Edison.
- The appointment was announced in a press release furnished as Exhibit 99.1.
Compensation, Contingencies, and Unusual Items
The employment agreement provides for participation in the company’s employee stock option plan and employee benefit programs. The 100,000 stock options are to be awarded within 10 days of appointment and are subject to the company’s applicable award terms.
If Mr. Leffler is terminated without cause or resigns for good reason, subject to execution of a release, he may receive a lump-sum severance payment based on one-twelfth of annual base salary for each full year of employment, with a minimum of six months and a maximum of two years of then-current base salary. Separate benefits and enhanced severance apply for qualifying termination events following a change in control.
The filing states that Mr. Leffler has no family relationship with any director or executive officer and is not party to a transaction requiring disclosure under Item 404(a) of Regulation S-K. No additional business outlook or financial guidance is provided.
Investor Verification Checklist
- Verify the complete employment agreement filed as Exhibit 10.1, including option vesting terms and change-in-control provisions.
- Confirm the timing and terms of the 100,000 stock-option award and its potential dilution.
- Assess the potential cash cost of salary, bonus, signing bonus, and severance obligations.
- Review subsequent filings for changes in CFO status, compensation, or equity awards.
- Use the company’s periodic financial filings—not this 8-K—to verify operating performance, cash balances, debt, liquidity, and guidance.